CluePoints’ Launch of Post-COVID Trial Assurance Solution
CluePoints has launched a new Post-COVID Trial Assurance Solution as part of its mission to build safer, more efficient trials for patients, sponsors and CROs.
The new CluePoints Post-COVID Trial Assurance Solution offers study teams the opportunity to assess the quality of their data within a defined timeline and with limited resources. It goes beyond traditional key risk indicators to evaluate 100% of the clinical data to assess expected risks, while also identifying data anomalies which might indicate unexpected risks—surfacing issues which can be found by leveraging CluePoints’ Central Statistical Monitoring Platform.
Furthermore, CluePoints can provide Data Scientists to do all the heavy lifting and work with the study team to support plans to identify and resolve issues and document what’s been done to mitigate the risks.
The Post-COVID Trial Assurance Solution includes (subject to expert consultation as to what will work best on your specific study or studies):
- Comprehensive Central Statistical Analysis
The comprehensive statistical analysis provides a complete unsupervised analysis of all clinical data to uncover unknown risks in your trial
- Key Risk Indicators (KRIs)
The Key Risk Indicator module provides a convenient way to monitor how sites are performing versus the metrics that are important to the trial
- Patient Profiles
By coupling Patient Profiles with Central Statistical Monitoring, patients can be ranked by their relative degree of atypicality, allowing clinical teams to get the patients that need it reviewed faster
- Duplicate Patients
If the existence of ‘Professional Patients’ participating in the trial is a concern, CluePoints’ Duplicate Patients module can identify them so that any sign of enrolment abuse can be investigated and addressed
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
